Shionogi’s Mulpleo for severely low levels of blood platelets caused by liver disease is to be made available to NHS patients across the UK after authorities in England and Scotland said it
Patients in England are to get easier access to Merck KGaA’s multiple sclerosis drug Mavenclad after NICE dropped requirements for a special MRI scan before prescription.
NICE has recommended two of GW Pharma's cannabis-based medicines, the first time that medicines derived from the plant have been recommended for NHS funding.
NICE has said Roche's Tecentriq (atezolizumab) should not get regular NHS funding in first draft guidance as a treatment for metastastic triple negative breast cancer (TNBC), saying that it
